BiotechTube

GR-MD-02 + Placebo

Phase 2Completed
0 watching 0 views this week⚡ Active
44
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Nonalcoholic Steatohepatitis

Conditions

Nonalcoholic Steatohepatitis

Trial Timeline

Sep 1, 2015 → Sep 27, 2016

NCT ID
NCT02421094

About GR-MD-02 + Placebo

GR-MD-02 + Placebo is a phase 2 stage product being developed by Galectin Therapeutics for Nonalcoholic Steatohepatitis. The current trial status is completed. This product is registered under clinical trial identifier NCT02421094. Target conditions include Nonalcoholic Steatohepatitis.

Hype Score Breakdown

Clinical
17
Activity
12
Company
2
Novelty
5
Community
5

Clinical Trials (3)

NCT IDPhaseStatus
NCT02421094Phase 2Completed
NCT02462967Phase 2Completed
NCT01899859Phase 1Completed

Competing Products

20 competing products in Nonalcoholic Steatohepatitis

See all competitors
ProductCompanyStageHype Score
VK2809 + PlacebosViking TherapeuticsPhase 2
47
TERN-501 + TERN-101Terns PharmaceuticalsPhase 2
49
TERN-101Terns PharmaceuticalsPhase 2
49
TERN-201Terns PharmaceuticalsPhase 1
30
LanifibranorInventivaPhase 2
47
IVA337 + Placebo + EmpagliflozinInventivaPhase 2
47
IVA337 + PlaceboInventivaPhase 3
72
Colesevelam HclDaiichi SankyoPhase 2
52
Tirzepatide + PlaceboEli LillyPhase 2
52
AZD2693AstraZenecaPhase 2
52
Roflumilast + Pioglitazone + Placebo + PlaceboAstraZenecaPhase 2
52
MK-3655 + PlaceboMerckPhase 2
52
Efinopegdutide 20 mg/mL + Semaglutide 1.34 mg/mLMerckPhase 2
52
SEL + Placebo to match SEL 6 mg + Placebo to match SEL 18 mgGilead SciencesPhase 3
76
Seladelpar + PlacebosGilead SciencesPhase 2
51
CilofexorGilead SciencesPhase 1
32
Firsocostat + FenofibrateGilead SciencesPhase 1
32
GS-9674 + Placebo to match GS-9674Gilead SciencesPhase 2
51
SEL + FIR + CILO + Placebo to match FIR + Placebo to match CILO + Placebo to match SELGilead SciencesPhase 2
51
GS-9450 + GS-9450 PlaceboGilead SciencesPhase 2
51

Other Products from Galectin Therapeutics

belapectin + PlaceboPhase 2/3
57
GR-MD-02Phase 2
44
GM-CT-01 plus 5-FluorouracilPhase 2
44
GR-MD-02 + PlaceboPhase 2
44
GM-CT-01 + 5-Fluorouracil, Leukovorin, bevacizumabPhase 2
44